Drug Development

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Articles

Bi-layer tablets are an under-utilized option that can be employed to help reduce treatment burden, but their formulation is more complex than for conventional monolayer products.

Formulating Tablets Layer by Layer

Susana Saldanha, PharmD, is formulation development scientist at Hovione.

Beatriz Fernandes, MSc, is a formulation development scientist at Hovione

João Ventura, PhD, is director of Technology Development and Licensing at Hovione Technology.

Particle performance in a DPI can be optimized by fine-tuning the formulation and manufacturing process parameters.

Spray Drying as an Enabling Technology for Inhalation Drug Delivery

CMOs and CDMOs adjust business processes as demand for COVID-19 treatments and non-pandemic related therapies puts pressure on the bio/pharma industry.

Balancing Pressing Priorities

Vaccines define the path to putting the pandemic in the rear-view mirror.

Avoiding Delays on the Road to Normalcy

Torkel Gren is senior director, Technology Officer & Strategic Investments at Recipharm.

Modified-release dosage forms present new opportunities for drug developers and can help overcome challenges, such as short biological half-life or poor bioavailability due to degradation in the stomach. 

Modified Release: A Pathway to More Patient-Friendly Medication

Pharmapack Europe event organizers have revealed increased levels of innovation in drug delivery across the industry, substantiated by the level of regulatory approvals.

Pharmapack Innovation Index Reveals Continuing Innovation in Drug Delivery Across Europe

Reports of myocarditis and pericarditis following Pfizer-BioNTech and Moderna vaccinations prompts warnings.

FDA Adds Warning to mRNA Vaccine Fact Sheets

The European Commission has purchased an additional 150 million doses of Moderna’s COVID-19 vaccine for delivery in 2022.

EC Orders 150 Million Additional Doses of Moderna’s COVID-19 Vaccine

EMA's recent positive opinion for a recombinant vaccine for rabbits developed using Algenex’s proprietary and patent protected Baculovirus vector-mediated expression platform, CrisBio, should push the full commercialization of the platform forward.

EMA Issues Positive Opinion for CrisBio Developed Vaccine, Validating the Platform

CureVac’s first-generation COVID-19 vaccine candidate, CvnCoV, did not meet efficacy targets in a second interim analysis. 

Formulation and Drug Delivery